AEI aeris environmental ltd

EPA backs 99.99% attack on COVID, golden staph?

  1. 1,219 Posts.
    lightbulb Created with Sketch. 599
    Will the US Environmental Protection Agency agree to approve/list Aeris Active, AEI's lead disinfectant product?

    I believe a positive announcement is imminent.

    Why?  Five days ago - on July 3 - AEI posted a Market Update.

    The Update included this statement: "Aeris is please to announce that it has had independent testing conducted in Europe by APEX Bio Solutions in Serre-les-Sapins, France for its proprietary Aeris Active product.

    "Following the relevant EN testing, Aeris Active achieved success on all parameters and, specifically, on a seven-day residual Coronavirus claim, validating both the performance and differentiation of the Company’s products (refer table below)."

    To me, the fact that Aeris published an internal document containing product intelligence relevant to its emergency fast tracking EPA application, implicitly flagged the likelihood of EPA approval.

    Further, publication of the important document may have had something to do with new protocols adopted by the ASX.

    The ASX now wants listed companies to substantiate claims about the effectiveness of their products in addressing COVID-19 issues.

    The ASX, it seems, reviewed the Aeris test results and ticked off their release.

    Aeris reveals in the table that Aeris Active has >4 log efficacy (99.99%) in killing coronavirus residual during seven days and 200 touches.

    But there's more: The group  reveals that Aeris Active has a >4 log efficacy in killing Staphylococcus aureus (golden staph).

    It can kill the residual effect of golden staph during seven days and for 200 touches.

    AEI would have furnished these independently-tested Aeris Active efficacy credentials to the EPA.

    And the EPA would then be faced with two basic decisions - whether to:

    1. Facilitate use of a potent weapon to kill coronavirus and

    2. Facilitate use of a potent weapon to kill hospital superbug, golden staph.

    I'm tipping the EPA will deliver emphatic approval.

    And if it does so, AEI will receive cascading financial rewards - worth much more than today's anticipatory $15m boost in market capitalization.
    Last edited by Medify: 08/07/20
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
4.0¢
Change
0.002(5.26%)
Mkt cap ! $9.839M
Open High Low Value Volume
4.0¢ 4.0¢ 4.0¢ $4K 100K

Buyers (Bids)

No. Vol. Price($)
1 25000 4.0¢
 

Sellers (Offers)

Price($) Vol. No.
4.5¢ 150000 1
View Market Depth
Last trade - 14.37pm 25/07/2025 (20 minute delay) ?
AEI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.